PARSIPPANY, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin® and will continue toward completion.
